Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2021-10-12 00:00:00 ET · period of report 2021-10-07 · accession 0001140361-21-034424 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-10-12 | 2021-10-07 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +43.8K | 43.8K | New | $0 |
| D | 2021-10-12 | 2021-10-07 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +436.9K | 436.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-07 | A | A | 43,750 | $0.00 | 43,750 | D | — | — | (F1) Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| 2 | Derivative | Stock Option (Right to buy) | 2021-10-07 | A | A | 436,929 | $0.00 | 436,929 | D | $16.00 · — to 2031-10-07 | 436,929 Common Stock | (F2) These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |